Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Cardiovasc Drugs ; 19(6): 525-539, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30941708

RESUMO

Direct oral anticoagulants (DOACs) have been developed as a viable and in some cases superior alternative to warfarin. These agents have overcome some of the limitations of warfarin, which has a narrow therapeutic window and many food and drug interactions. DOACs have been demonstrated to have a more predictable and reliable pharmacology and, unlike warfarin, do not require frequent monitoring of anticoagulant effect. For these reasons, the use of DOACs is increasing. Despite the many positive attributes of these agents, limitations and contraindications do exist. An understanding of the pharmacology, indications, and contraindications is therefore crucial for effective patient management. We review the available agents to aid in effective drug utilization.


Assuntos
Anticoagulantes/uso terapêutico , Antitrombinas/farmacologia , Antitrombinas/uso terapêutico , Inibidores do Fator Xa/farmacologia , Inibidores do Fator Xa/uso terapêutico , Acidente Vascular Cerebral/prevenção & controle , Administração Oral , Anticoagulantes/efeitos adversos , Anticoagulantes/farmacologia , Antitrombinas/efeitos adversos , Antitrombinas/farmacocinética , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Uso de Medicamentos , Inibidores do Fator Xa/efeitos adversos , Inibidores do Fator Xa/farmacocinética , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...